Ms. Samira Sakhia reports

KNIGHT THERAPEUTICS ANNOUNCES RELAUNCH OF MYFEMBREE® IN CANADA

Knight Therapeutics Inc. has relaunched Myfembree (relugolix/estradiol/norethindrone acetate) in Canada.

In June, 2024, Knight and Sumitomo Pharma America Inc. (SMPA) announced that Knight and SMPA's affiliates had entered into exclusive license and supply agreements to commercialize Myfembree (relugolix/estradiol/norethindrone acetate), Orgovyx (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products.

Myfembree is a fixed-dose combination of relugolix, estradiol and norethindrone acetate, and is the first oral prescription treatment for both the management of heavy menstrual bleeding associated with uterine fibroids and the management of moderate to severe pain associated with endometriosis in premenopausal women. Myfembree was approved by Health Canada in September of 2023 and was launched in February, 2024. Based on IQVIA, the total gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist sales for endometriosis and uterine fibroids in Canada is estimated at $45-million and has been growing at a five-year CAGR (compound annual growth rate) of 8 per cent. According to IQVIA Canada, in 2024, the sales of Myfembree were approximately $2.9-million.

"The relaunch of Myfembree provides physicians an effective treatment option for the management of uterine fibroids and endometriosis, conditions that continue to impact so many women," said Samira Sakhia, president and chief executive officer of Knight. "Myfembree strengthens our women's health portfolio and benefit from the synergies of our existing commercial and medical infrastructure."

About Myfembree

Myfembree (relugolix 40 milligrams, estradiol one mg and norethindrone acetate 0.5 mg tablets) was approved by Health Canada in September, 2023, making it the first oral prescription treatment for both the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis in premenopausal women.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.